Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Ars Pharmaceuticals Inc (SPRY)

Ars Pharmaceuticals Inc (SPRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,316,857
  • Shares Outstanding, K 97,185
  • Annual Sales, $ 30 K
  • Annual Income, $ -54,370 K
  • EBIT $ -61 M
  • EBITDA $ -67 M
  • 60-Month Beta 0.90
  • Price/Sales 44,672.70
  • Price/Cash Flow N/A
  • Price/Book 6.65

Options Overview Details

View History
  • Implied Volatility 72.41% ( +2.72%)
  • Historical Volatility 70.88%
  • IV Percentile 22%
  • IV Rank 46.87%
  • IV High 130.73% on 01/12/24
  • IV Low 20.97% on 06/10/24
  • Put/Call Vol Ratio 0.01
  • Today's Volume 180
  • Volume Avg (30-Day) 614
  • Put/Call OI Ratio 0.50
  • Today's Open Interest 11,490
  • Open Int (30-Day) 17,999

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.09
  • Number of Estimates 3
  • High Estimate 0.26
  • Low Estimate -0.27
  • Prior Year -0.07
  • Growth Rate Est. (year over year) -28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.01 +3.77%
on 11/21/24
18.51 -27.07%
on 11/11/24
-3.22 (-19.26%)
since 10/21/24
3-Month
11.00 +22.73%
on 09/06/24
18.51 -27.07%
on 11/11/24
+0.10 (+0.75%)
since 08/21/24
52-Week
4.65 +190.32%
on 11/28/23
18.51 -27.07%
on 11/11/24
+8.80 (+187.23%)
since 11/21/23

Most Recent Stories

More News
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

SPRY : 13.39 (-1.18%)
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States

SPRY : 13.39 (-1.18%)
ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences

SPRY : 13.39 (-1.18%)
ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

SPRY : 13.39 (-1.18%)
3 Top 100 Stocks to Buy Moving Up 20 Spots or More

As investors might know, September is historically the worst month for stock returns. The S&P 500 has averaged a 5.8% decline in September in the past four years—these three Top 100 Stocks to Buy look...

RAIL : 9.64 (-8.28%)
SPRY : 13.39 (-1.18%)
GGAL : 55.96 (-2.95%)
Stocks Settle Higher on Favorable PPI Report

The S&P 500 Index ($SPX ) (SPY ) Tuesday closed up +1.68%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +2.50%. US stocks settled...

$SPX : 5,953.21 (+0.61%)
SPY : 593.58 (+0.52%)
$DOWI : 43,876.78 (+1.08%)
DIA : 439.10 (+1.11%)
$IUXX : 20,747.51 (+0.39%)
QQQ : 504.50 (+0.26%)
ZNZ24 : 109-175 (-0.13%)
SBUX : 100.09 (+1.86%)
NVDA : 146.65 (+0.52%)
INTC : 24.44 (+1.79%)
ARM : 132.93 (-0.58%)
MRVL : 93.04 (+3.54%)
Stocks Rally on a Muted US July PPI Report

The S&P 500 Index ($SPX ) (SPY ) today is up +0.92%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.37%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.50%. US stocks today are moderately...

$SPX : 5,953.21 (+0.61%)
SPY : 593.58 (+0.52%)
$DOWI : 43,876.78 (+1.08%)
DIA : 439.10 (+1.11%)
$IUXX : 20,747.51 (+0.39%)
QQQ : 504.50 (+0.26%)
ZNZ24 : 109-175 (-0.13%)
SBUX : 100.09 (+1.86%)
NVDA : 146.65 (+0.52%)
INTC : 24.44 (+1.79%)
MRVL : 93.04 (+3.54%)
AMD : 137.44 (-0.12%)
Stocks Climb After US July PPI Rises Less Than Expected

The S&P 500 Index ($SPX ) (SPY ) today is up +0.80%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.51%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.14%. US stocks today are moving higher,...

$SPX : 5,953.21 (+0.61%)
SPY : 593.58 (+0.52%)
$DOWI : 43,876.78 (+1.08%)
DIA : 439.10 (+1.11%)
$IUXX : 20,747.51 (+0.39%)
QQQ : 504.50 (+0.26%)
ZNZ24 : 109-175 (-0.13%)
SBUX : 100.09 (+1.86%)
NVDA : 146.65 (+0.52%)
ARM : 132.93 (-0.58%)
MU : 103.00 (+4.71%)
AMD : 137.44 (-0.12%)
Why Shares of ARS Pharmaceuticals Are Plummeting on Wednesday

The company received a Complete Response Letter from the FDA regarding its lead therapy.

SPRY : 13.39 (-1.18%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or the "Company") (NASDAQ: SPRY). Such...

SPRY : 13.39 (-1.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ARS Pharmaceuticals Inc. is dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions which could lead to anaphylaxis. The company is developing neffy(TM) an intranasal epinephrine product in clinical development for patients and their caregivers...

See More

Key Turning Points

3rd Resistance Point 14.62
2nd Resistance Point 14.24
1st Resistance Point 13.90
Last Price 13.39
1st Support Level 13.18
2nd Support Level 12.80
3rd Support Level 12.46

See More

52-Week High 18.51
Last Price 13.39
Fibonacci 61.8% 13.22
Fibonacci 50% 11.58
Fibonacci 38.2% 9.94
52-Week Low 4.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar